China Meheco subsidiary's ganciclovir injection passes consistency evaluation

China Meheco's wholly-owned subsidiary, Hainan Generallink Kangli Pharmaceutical Co., Ltd. (Kangli Pharmacy), announced its ganciclovir for injection has passed the generic drug consistency evaluation by the National Medical Products Administration. This approval covers both 0.25g and 0.5g specifications, with the drug used to treat life-threatening or vision-threatening cytomegalovirus infections in immunocompromised patients and to prevent such infections in organ transplant recipients.

The company invested approximately CNY 3.94 million in the drug as of the disclosure date. While Kangli Pharmacy did not sell the drug in 2024, the domestic market for ganciclovir for injection recorded approximately CNY 259 million in sales in public hospitals and grassroots medical terminals in 2024. This approval is expected to bolster the drug's market position through favorable medical insurance and procurement policies.

Meanwhile, China Meheco is involved in a lawsuit concerning a performance compensation agreement, with a total amount of CNY 139.4041 million. The company has appealed the first-instance judgment, and the second-instance hearing has not yet been scheduled, indicating uncertainty regarding the final outcome.